Tanox Inc. has
announced that its
shareholders have approved Genentech's offer to acquire the company for $20 per share ($919 million). Tanox is a biotechnology company located in
Houston, TX that focuses on discovery and development of biotherapeutics. Tanox's approved drug Xolair® (omalizumab) is the first anti-IgE
antibody on the market. As stated on
Tanox's website, Xolair® is approved for the treatment of asthma in adults
and children age 12 and over. Tanox also
has three additional monoclonal antibodies in various stages of clinical
development. The actual acquisition of
Tanox by Genentech is now subject to approval by regulators.
Jason Derry, Ph.D., who graduated with honors from DePaul University
College of Law, is a molecular biologist and founding author of Patent Docs.
Comments